

## Phytochemicals, Cytotoxicity, Inhibitory Effect on Nitric Oxide Production and Alpha-Glucosidase Activity, and DPPH Scavenging Activity of Leaf Extract from *Gymnema inodorum* (Lour.) Decne

Supasorn Sakuljaitrong<sup>1</sup>, Nopparat Buddhakala<sup>2,\*</sup>,  
Moragote Buddhakala<sup>3</sup>, Sasiprapha Asawawibul<sup>4</sup>, Saowanee Buatone<sup>5</sup>,  
Yaowapar Tongaram<sup>6</sup> and Chusri Talubmook<sup>7</sup>

<sup>1</sup>Department of Biology, Faculty of Science and Technology, Loei Rajabhat University, Loei 42000, Thailand

<sup>2</sup>Division of Biology, Faculty of Science and Technology, Rajamangala University of Technology Thanyaburi, Pathum Thani 12110, Thailand

<sup>3</sup>Division of Physics, Faculty of Science and Technology, Rajamangala University of Technology Thanyaburi, Pathum Thani 12110, Thailand

<sup>4</sup>Division of Food Science and Technology Management, Faculty of Science and Technology, Rajamangala University of Technology Thanyaburi, Pathum Thani 12110, Thailand

<sup>5</sup>Rangsit Science Centre for Education, Pathum Thani 12110, Thailand

<sup>6</sup>Chulachomklao Royal Military Academy, Nakhon Nayok 2600, Thailand

<sup>7</sup>Department of Biology, Faculty of Science, Mahasarakham University, Maha Sarakham 44150, Thailand

(\*Corresponding author's e-mail: [nopparat\\_b@rmutt.ac.th](mailto:nopparat_b@rmutt.ac.th))

Received: 26 December 2022, Revised: 27 January 2023, Accepted: 6 February 2023, Published: 19 February 2023

### Abstract

Investigation of phytochemicals, cyto-toxicity, inhibitory effect on nitric oxide (NO) production and  $\alpha$ -glucosidase activity, and DPPH scavenging activity of leaf extract from *Gymnema inodorum* (Lour.) Decne (LEGI) revealed that GC-MS analysis demonstrated the presence of 83 phytochemicals with 5 main compounds i.e. Phytol (18.14 %), n-Hexadecanoic acid (12.45 %), 9,12-Octadecadienoic acid (Z,Z)-(3.92 %), 9,12,15-Octadecatrienoic acid, (Z,Z,Z)-(10.39 %) and Betulin (8.56 %), and 78 trace compounds in LEGI. MTT assay to investigate cytotoxicity showed that LEGI exhibited low cytotoxicity to the RAW 264.7 macrophages with IC<sub>50</sub> of 128.77 $\pm$ 2.82  $\mu$ g/mL. Treatment with the LEGI significantly inhibited nitric oxide (NO) production, an inflammatory mediator, in the LPS-stimulated RAW 264.7 cells. At the concentration of 50 mg/mL, LEGI inhibited NO production by 16.73 $\pm$ 1.52 % which was less than Diclofenac did (27.07 $\pm$ 1.81 %). The  $\alpha$ -glucosidase inhibitory activity to determine the antidiabetic activity showed that LEGI exhibited the inhibition on  $\alpha$ -glucosidase activity with IC<sub>50</sub> of 0.34 mg/mL, which was less potent than Acarbose (IC<sub>50</sub> of 0.20 mg/mL). Assay of 2,2-diphenyl-2-picrylhydrazyl- hydrate (DPPH) radical scavenging to examine antioxidant activity revealed that LEGI demonstrated less potent DPPH scavenging activity compared to Butylated hydroxytoluene, BHT with IC<sub>50</sub> of 0.43 vs 0.36 mg/mL, respectively. These results indicate that the leaf extract from *G. inodorum* possesses anti-inflammatory, antidiabetic and antioxidant activities that can be developed and used as natural agents for the treatment of diseases related to these activities.

**Keywords:** *Gymnema inodorum*, Chemical components,  $\alpha$ -glucosidase, DPPH, NO production, Phytochemicals, Inflammatory mediator

### Introduction

*Gymnema inodorum* (Lour.) Decne (GI) belongs to the Family Asclepiadaceae. GI is indigenous in Southeast Asia including Thailand [1]. It has been popularly consumed as vegetable, used as herbal remedy and commercial herb tea products especially in the northern and northeastern parts of Thailand [2,3,4]. GI has high nutritional values. Apart from nutritional value, its leaves have therapeutic value in diabetes mellitus, rheumatic arthritis and gout [5]. It is also used to treat various ailments for example asthma, eye irritation, chronic cough, trouble breathing, constipation, and abdominal pain due to indigestion. In addition, it has been reported to possess anti-microbial activities, anti-hypercholesterolemic activity, and anti-inflammatory properties [6].

GI leaves contain some nutritional values such as protein, fat, and fiber contents [7] and many phytochemicals including phenolics, flavonoids, terpenoids, and glycoside [1,8,9]. Total phenolic content was found in both the narrow and board leaves of GI [7]. Pregnane glycosides, gymnosides A and B, tinctoroside B, tinctoroside C, and gymnepregoside F were isolated from the GI leaves [9,10]. GI juice has high amounts of vitamin E and  $\beta$ -carotene [11,12]. GI extract has been reported to have triterpene glycoside, (3 $\beta$ , 16 $\beta$ )-16,28-dihydroxyolean-12-en-3-yl-O- $\beta$ -D-gluco-pyranosyl- $\beta$ -D glucopyranosiduronic acid (GIA1) [13] and 16 volatile compounds [4]. Total phenolic and flavonoid contents were more intensive in the GI ethanolic extracts [12].

MTT (3-[4, 5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay revealed that GI extract at a concentration of 62.5  $\mu$ g/mL exhibited noncytotoxicity in Caco-2 cells [13] and may not be toxic to the liver and kidney in mice [1]. GI tea did not affect hepatic and renal functions [14]. Moreover, long-term consumption of GI for 28 days did not cause hepatotoxicity [1].

GI leaf extract exhibited anti-inflammatory effects by inhibiting the NO production in LPS-activated RAW 264.7 macrophages [12] and suppressing nitric oxide (NO) and downregulation of the expression of inducible nitric oxide synthase (iNOS) in LPS plus IFN- $\gamma$ -induced RAW264.7 cells [4].

GI has been reported to possess a hypoglycemic effect. Its leaves are used as an effective herbal medicine for the prevention and treatment of diabetes [12] and used as an antidiabetic functional food or tea [15]. GI water leaf extract decreased blood glucose in alloxan-induced diabetic rats [16,17]. Consumption of GI leaf extract can significantly decrease peak plasma glucose [3]. Phenolic content and some bioactive compounds containing in its leaves can control blood sugar levels [7]. GI extract exhibited antidiabetic activity in high-fat diet and STZ diabetic rats as well [18]. Gymnepregoside F, gymnosides A and B, tinctoroside B, and tinctoroside C isolated from GI leaves can inhibit  $\alpha$ -glucosidase activity [9].

The methanolic leaf extract of GI showed the highest level of antioxidant activity of 43 edible plants belonging to 8 families in Thailand [8]. The ethanolic GI leaf extract exhibited free radical scavenging effect on the DPPH assay [12]. PCL assay also demonstrated the antioxidant property of GI extract [19].

The biological activities including anti-inflammatory, antidiabetic and antioxidant activities of GI leaves and leaf extract have been investigated. However, mechanisms of action on these activities have not much been reported. The present study was therefore undertaken *in vitro* to investigate phytochemicals using GC-MS, anti-inflammatory activity by measuring NO production, antidiabetic activity using  $\alpha$ -glucosidase inhibitory activity, and antioxidant activity using DPPH radical scavenging activity and to elucidate the underlying mechanism involved the activities of ethanol leaf extract from *G. inodorum*. And also, determination of cytotoxicity using MTT assay was carried out to ensure for safety applications.

## Materials and methods

### Plant materials

The plant used in the present study was fresh mature and healthy leaves of *Gymnema inodorum* (Lour.) Decne and was purchased from a local garden in Chiang Mai province, Thailand. The plant leaves were identified and authenticated by Dr. Panarat Thongpoem, a lecturer in the Division of Biology, Faculty of Science and Technology, Rajamangala University of Technology Thanyaburi, Pathum Thani, Thailand. The authentic samples with reference SCI/BIO/GI 2020-001 have been submitted to the herbarium in the Department of Biology, Faculty of Science and Technology, Rajamangala University of Technology Thanyaburi (RMUTT).

### Preparation of plant extract

The plant leaves were cleaned and removed all impurities by washing thoroughly with tap water. The leaf samples were cut into small pieces, dried in shade and further dried in a hot air oven at 60 °C. The dried leaves were ground to fine powder using an electric grinder, and extracted. Extraction of the plant samples was performed using the macerating process according to Buddhakala and Talubmook [20]. The powder sample was mixed with 95 % ethanol at a ratio of 100 g : 400 mL. The maceration of the mixture was carried out at room temperature for 7 days with intermittent stirring. After the maceration period, the mixture was filtered through Whatman No. 1 filter paper. The extraction process was repeated for a second time by adding 400 mL of 95 % ethanol to the mixture residue. The filtrates were pooled and concentrated using a rotary evaporator (Heidolph Laborota 4000, Germany) at 50 °C followed by oven-dried at 40 °C until paste-like mass extract was formed. The leaf extract of *G. inodorum* (LEGI) was kept in an air-tight glass container at -20 °C before the commencement of the experiments.

### Determination of phytochemicals

Phytochemicals in LEGI were determined by using a gas chromatography-mass spectrometry (GC-MS) instrument (Agilent7890B GC System) equipped with a capillary column (Agilent HP-5MS UI; 30 m length  $\times$  0.25 mm internal diameter and 0.25  $\mu$ m film thickness). For GC-MS detection, an electron ionization system was operated in the electron impact mode with an ionization energy of 70 eV. The temperature process of the column was initially at 80 °C for 6 min, followed by an increase of 5 °C/min to 200 °C and then 20 °C/min to 250 °C, and the ion-source temperature was 200 °C. The oven temperature was programmed from 45 °C (2 min), with an increase of 7 °C/min to 250 °C and maintained for 25 min. The carrier gas was helium with a flow rate of 1.0 mL/min. The mass spectrometer was operated in electron ionization with an acquisition mode scan of 35 - 500 amu. The ion source and transfer line temperatures were kept at 250 °C. The injection volume of 1  $\mu$ L of the sample (0.1 % in absolute methanol) was split at a ratio of 250 : 1. The phytochemical components of LEGI were identified by comparison with standards, on the basis of their mass spectral fragmentation using the National Institute of Standards and Technology (NIST) and Wiley GC-MS libraries [13]. Identification of essential oil components by Gas Chromatography/mass Spectrometry. Allured Publishing Corporation. Carol Stream, IL, USA).

### Determination of cytotoxicity

The macrophage cells, RAW 264.7 cells, were purchased from the American Type Culture Collection, ATCC®TIB-71™, USA. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM, ATCC® 30-2002™ USA) supplemented with 5 % fetal bovine serum and 1 % antibiotics penicillin-streptomycin at 37 °C in a 5 % CO<sub>2</sub> incubator. The cells at a density of  $1 \times 10^5$  cells/mL were prepared in a 25 cm<sup>3</sup> flask and incubated in a 5 % CO<sub>2</sub> incubator at 37 °C. After 24 h, the cultured medium was removed and the cells were washed twice with PBS. DMEM in a volume of 2 - 3 mL was added to the flask. The cells were counted and diluted to a density of  $1 \times 10^5$  cells/ml in a 96-well plate for the determination of cell viability.

Cell viability was carried out using 3-[4, 5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay, a colorimetric assay which is based on the conversion of MTT solution into formazan crystals by living cells. In this study, MTT assay was conducted to determine the viability of the Raw 264.7 cells after treatment with LEGI solutions (25, 50, 100, 150, 200, 250, 500, 750 and 1000  $\mu$ g/mL). The RAW 264.7 cells ( $1 \times 10^5$  cells/well) were cultured in the 96-well plates containing DMEM cultured medium. The plates were incubated overnight at 37 °C in a 5 % CO<sub>2</sub> incubator for 24 - 48 h. The cultured medium was removed from each well and washed with PBS. LEGI solutions prepared by dissolving in dimethyl sulfoxide (DMSO) with a final DMSO concentration < 0.1 % (v/v), LPS (1  $\mu$ g/mL), positive control (10 % DMSO), and negative control (Blank) in a volume of 200  $\mu$ L/well were added to each well and incubated in a 5 % CO<sub>2</sub> incubator at 37 °C for 24 h. The cells were treated with various concentrations of LEGI solution for 24 h. The cultured medium was removed. A volume of 50  $\mu$ L/well of 5 mg/mL MTT solution in PBS and a volume of 150  $\mu$ L/well of fresh cultured medium were added to each well. The plates were incubated at 37 °C for 24 h. The solutions in the plates were removed. Then 100  $\mu$ L of DMSO was added to each well and shaken gently for 15 min, in order to dissolve the formazan crystals. After gently shaking, cell viability was quantified by an absorbance measurement. The absorbance was measured at 570 nm using micro-plate reader (Multiskan Go, Thermo/Scientific, Netherlands). The percentage of the cell viability was computed using the following equation:

$$\% \text{ cell viability} = (\text{OD of treated sample} / \text{OD of untreated sample}) \times 100$$

Cytotoxicity of LEGI was expressed as LC<sub>50</sub> (the concentration of LEGI required to produce 50 % cell viability of the RAW 264.7 macrophages).

The concentrations of LEGI which showed more than 80 % viable cells were used for determination of NO production.

### Determination of NO production

NO production was determined by measuring nitrite concentration in the cultured medium. The nitrite concentration was quantified using the Griess assay, a simple technique that is widely used for the quantification/detection of NO [21]. The basic reaction involves reacting the Griess reagent, sulphanilamide and N-1-naphthylethylenediamine dihydrochloride (NED), to form a stable azo compound.

The RAW 264.7 cells were cultured in DMEM and incubated at 37 °C in 5 % CO<sub>2</sub>. The viable cells were counted and diluted with a medium to give a concentration of  $1 \times 10^5$  cells/mL. These cells were cultured in each well of a 96-well plate and allowed to adhere for 1 h at 37 °C under 5 % CO<sub>2</sub>. After that,

the cultured medium was removed from each well and washed with PBS. The LEGI solutions, positive control (Diclofenac) and LPS were added to the well and incubated in a 5 % CO<sub>2</sub> at 37 °C for 24 h. After the incubation period, the cultured medium was collected for the determination of NO production. The cultured medium treated with LEGI in a volume of 50 µL/well was added to the well. Sulfanilamide solution (50 µL) and NED solution (50 µL) were also added to the well and incubated at room temperature in dark place for 5 - 10 min. Absorbance (A) of the mixture solution was measured at 570 nm using micro-plate reader. Percentage (%) nitric oxide (NO) production was calculated using the following equation and compared to a positive control (Diclofenac):

$$\% \text{ NO production} = (A \text{ extract} + \text{LPS} / A \text{ control} + \text{LPS}) \times 100$$

#### Determination of $\alpha$ -glucosidase inhibitory activity

An assay of  $\alpha$ -glucosidase inhibitory activity was carried out to determine the antidiabetic activity of LEGI. Inhibition on  $\alpha$ -glucosidase activity was assessed according to [22], with slight modifications. Briefly, 60 µL of sample solution and 50 µL of 0.1 M phosphate buffer containing  $\alpha$ -glucosidase solution (0.2 U/mL) were incubated in 96-well plate at 37 °C for 20 min. After pre-incubation, 50 µL of the substrate (5 mM *p*-nitrophenyl- $\alpha$ -D-glucopyranoside (*p*-NPG) solution in 0.1 M phosphate buffer, (pH 6.8) was added to each well and incubated at 37 °C for another 20 min. A volume of 160 µL of 0.2 M Na<sub>2</sub>CO<sub>3</sub> was then added to the well to terminate the reaction. The absorbance reading was recorded at 405 nm using the micro-plate reader and compared to the control which had 60 µL of buffer solution in place of the extract. For blank incubation (to allow for absorbance produced by the extract), the enzyme solution was replaced by buffer solution, and absorbance was recorded. Acarbose, a positive control of  $\alpha$ -glucosidase inhibitor was also assayed. The % inhibition on  $\alpha$ -glucosidase activity was calculated using the following equation:

$$\% \text{ inhibition} = [(Abs \text{ blank} - Abs \text{ sample}) / Abs \text{ blank}] \times 100$$

where Abs blank is the absorbance of the control without the test solution, and Abs sample is the absorbance of the sample with the test solution.

IC<sub>50</sub> value, the concentration of the LEGI required to inhibit 50 % of  $\alpha$ -glucosidase activity was determined and compared to Acarbose.

#### Determination of DPPH scavenging activity

DPPH (2, 2-diphenyl-2-picrylhydrazylhydrate) scavenging activity of LEGI was determined spectrophotometrically. Various concentrations of LEGI (25, 50, 100, 200 and 400 µg/mL) prepared by dissolving LEGI in methanol were added to solution of DPPH in methanol. The mixture was shaken vigorously and left to stand at room temperature in a dark place for 30 min. After that, the absorbance at 517 nm, the maximum absorbance of DPPH, was recorded as Abs sample using an ultraviolet/visible (U/V) spectrophotometer. A blank experiment was also carried out using the same procedure, and the absorbance was recorded as Abs blank. The experiments were carried out in triplicates [8]. The percentage DPPH radical scavenging activity was calculated using the following equation:

$$\% \text{ DPPH radical scavenging} = [(Abs \text{ blank} - Abs \text{ sample}) / Abs \text{ blank}] \times 100$$

where Abs blank is the absorption of blank sample, and Abs sample is the absorption of the LEGI tested solution.

DPPH radical scavenging activity of LEGI was expressed as LC50 (the concentration of LEGI required to inhibit 50 % of DPPH radical scavenging) and compared to that of butylated hydroxytoluene (BHT), an antioxidant compound.


#### Statistical analysis

The results were expressed as mean  $\pm$  standard error of the mean (SEM). The data were first tested for normality and homogeneity. A comparison of the control and treatment groups was performed using one-way analysis of variance (ANOVA). Least Significant Difference (LSD) was performed to verify differences among treatment groups. Differences of  $p < 0.05$  were considered statistically significant.

## Results and discussion

### Phytochemicals

GC-MS analysis demonstrated the presence of 83 phytochemicals with 5 main chemical components and 78 other prevalent compounds in LEGI. Retention time, compound name, molecular formula, and % of total of the chemical compounds were presented in **Figure 1** and **Table 1**. The first compound identified with less retention time (5.1833) was Z-8-Methyl-9-tetradecenoic acid whereas Betulin was the last compound identified which took the longest retention time (53.4554) for identification.



**Figure 1** GC/MS chromatogram of phytochemicals found in LEGI.

**Table 1** GC-MS of 83 chemical compounds found in LEGI.

| No. | TR (min) | Compound name                                       | Molecular formula                              | % of Total |
|-----|----------|---|--|------------|
| 1   | 5.1833   | Z-8-Methyl-9-tetradecenoic acid                     | C <sub>15</sub> H <sub>28</sub> O <sub>2</sub> | 0.60       |
| 2   | 6.9859   | Undecane, 2,6-dimethyl-                             | C <sub>13</sub> H <sub>28</sub>                | 0.61       |
| 3   | 8.1733   | 2-Pyrrolidinone                                     | C <sub>4</sub> H <sub>7</sub> NO               | 0.53       |
| 4   | 8.6226   | Benzenamine, N,N-dimethyl-                          | C <sub>8</sub> H <sub>11</sub> N               | 0.13       |
| 5   | 10.3181  | 4H-Pyran-4-one, 2,3-dihydro-3,5-dihydroxy-6-methyl- | C <sub>6</sub> H <sub>8</sub> O <sub>4</sub>   | 0.11       |
| 6   | 11.6018  | Benzoic acid  | C <sub>7</sub> H <sub>6</sub> O <sub>2</sub>   | 0.13       |
| 7   | 12.7411  | Benzofuran, 2,3-dihydro-                            | C <sub>8</sub> H <sub>8</sub> O                | 0.26       |
| 8   | 13.0620  | 1H-Pyrrole-2,5-dione, 3-ethyl-4-methyl-             | C <sub>7</sub> H <sub>9</sub> NO <sub>2</sub>  | 0.22       |
| 9   | 13.5648  | 2-Piperidinemethanol, .alpha.-ethyl-                | C <sub>8</sub> H <sub>17</sub> NO              | 0.23       |
| 10  | 13.7306  | 2,5-Pyrrolidinedione, 3-ethyl-3-methyl-             | C <sub>2</sub> H <sub>11</sub> NO <sub>2</sub> | 0.32       |
| 11  | 13.8964  | Acetic acid, phenyl-                                | C <sub>8</sub> H <sub>8</sub> O <sub>2</sub>   | 1.24       |
| 12  | 14.7468  | Indole  | C <sub>8</sub> H <sub>7</sub> N                | 0.41       |
| 13  | 15.3138  | Ethanone,1-(2-hydroxy-5methylphenyl)-               | C <sub>9</sub> H <sub>10</sub> O <sub>2</sub>  | 0.29       |
| 14  | 16.1108  | 2-Cyclopenten-1-one, 2-methyl-                      | C <sub>6</sub> H <sub>8</sub> O                | 0.19       |
| 15  | 16.9398  | Benzeneacetic acid, alpha.-oxo-, ethyl ester        | C <sub>10</sub> H <sub>10</sub> O <sub>3</sub> | 0.07       |
| 16  | 17.6422  | Tetradecane   | C <sub>14</sub> H <sub>30</sub>                | 0.63       |
| 17  | 18.3305  | alpha-Ionone  | C <sub>13</sub> H <sub>20</sub> O              | 0.05       |
| 18  | 18.7477  | 2-ethoxycarbonyl-5-oxo pyrrolidine                  | C <sub>7</sub> H <sub>11</sub> NO <sub>3</sub> | 0.09       |

| No. | TR (min) | Compound name   | Molecular formula                              | % of Total |
|-----|----------|---|--|------------|
| 19  | 18.9777  | 5,9-Undecadien-2-one, 6,10-dimethyl-, (Z)-                                | C <sub>13</sub> H <sub>22</sub> O              | 0.10       |
| 20  | 19.8067  | 3-Buten-2-one, 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-                     | C <sub>13</sub> H <sub>20</sub> O              | 0.12       |
| 21  | 20.5127  | 2,4-Di-tert-butylphenol   | C <sub>14</sub> H <sub>22</sub> O              | 0.08       |
| 22  | 20.8283  | 2(4H)-Benzofuranone, 5,6,7,7a-tetrahydro-4,4,7a-trimethyl-, (R)-          | C <sub>11</sub> H <sub>16</sub> O <sub>2</sub> | 0.29       |
| 23  | 21.4006  | Disulfide, di-tert-dodecyl  | C <sub>24</sub> H <sub>50</sub> S <sub>2</sub> | 0.07       |
| 24  | 21.9783  | Fumaric acid, ethyl 2-methylallyl ester                                   | C <sub>10</sub> H <sub>14</sub> O <sub>4</sub> | 0.12       |
| 25  | 22.0746  | 3-Methyl-4-phenyl-1H-pyrrole  | C <sub>11</sub> H <sub>11</sub> N              | 0.16       |
| 26  | 22.5292  | Hexadecane  | C <sub>16</sub> H <sub>34</sub>                | 0.71       |
| 27  | 22.5880  | 2-Dimethylaminobenzoic acid   | C <sub>9</sub> H <sub>11</sub> NO <sub>2</sub> | 0.72       |
| 28  | 23.3903  | 2,6,8-Trimethylbicyclo[4.2.0]oct-2-ene-1,8-diol                           | C <sub>11</sub> H <sub>18</sub> O <sub>2</sub> | 0.16       |
| 29  | 23.8771  | 2,3-Dioxabicyclo[2.2.2]oct-5-ene, 1-methyl-4-(1-methylethyl)-             | C <sub>10</sub> H <sub>16</sub> O <sub>2</sub> | 0.09       |
| 30  | 24.5189  | 3-Buten-2-one, 4-(4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]hept-1-yl) | C <sub>13</sub> H <sub>20</sub> O <sub>3</sub> | 0.24       |
| 31  | 24.5992  | 3-Hydroxy-7,8-dihydro-.beta.-ionol  | C <sub>13</sub> H <sub>20</sub> O <sub>2</sub> | 0.30       |
| 32  | 24.8345  | 4-(3-Hydroxybutyl)-3,5,5-trimethyl-2-cyclohexen-1-one                     | C <sub>13</sub> H <sub>22</sub> O <sub>2</sub> | 0.30       |
| 33  | 25.6047  | 6-Hydroxy-4,4,7a-trimethyl-5,6,7,7a tetra hydrobenzofuran-2(4H)-one       | C <sub>11</sub> H <sub>16</sub> O <sub>3</sub> | 0.09       |
| 34  | 26.1877  | Myristic acid   | C <sub>14</sub> H <sub>28</sub> O <sub>2</sub> | 1.69       |
| 35  | 26.7386  | (S,E)-4-Hydroxy-3,5,5-trimethyl-4-(3-oxobut-1-en-1-yl)cyclohex-2-enone    | C <sub>13</sub> H <sub>18</sub> O <sub>3</sub> | 0.37       |
| 36  | 26.7921  | Tetradecanoic acid, ethyl ester   | C <sub>16</sub> H <sub>32</sub> O <sub>2</sub> | 0.17       |
| 37  | 26.8991  | Octadecane  | C <sub>18</sub> H <sub>38</sub>                | 0.42       |
| 38  | 27.7121  | Neophytadiene   | C <sub>20</sub> H <sub>38</sub>                | 1.07       |
| 39  | 27.8298  | 2-Pentadecanone, 6,10,14-trimethyl-                                       | C <sub>18</sub> H <sub>36</sub> O              | 0.59       |
| 40  | 28.2042  | 9-Octadecenoic acid (Z)-  | C <sub>18</sub> H <sub>34</sub> O <sub>2</sub> | 0.46       |
| 41  | 28.5679  | Phytol, acetate   | C <sub>22</sub> H <sub>42</sub> O <sub>2</sub> | 0.33       |
| 42  | 29.2900  | 5,9,13-Pentadecatrien-2-one,6,10,14-trimethyl, (E,E)-                     | C <sub>18</sub> H <sub>30</sub> O              | 0.11       |
| 43  | 29.7767  | Palmitoleic acid  | C <sub>16</sub> H <sub>30</sub> O <sub>2</sub> | 0.17       |
| 44  | 30.3116  | n-Hexadecanoic acid   | C <sub>16</sub> H <sub>32</sub> O <sub>2</sub> | 12.45      |
| 45  | 30.7716  | Hexadecanoic acid, ethyl ester  | C <sub>16</sub> H <sub>36</sub> O <sub>2</sub> | 2.14       |
| 46  | 30.8571  | Icosane   | C <sub>20</sub> H <sub>42</sub>                | 0.16       |
| 47  | 31.6327  | Cyclopentadecanone, 2-hydroxy-  | C <sub>15</sub> H <sub>28</sub> O <sub>2</sub> | 0.12       |
| 48  | 32.0499  | Heptadecanoic acid  | C <sub>17</sub> H <sub>34</sub> O <sub>2</sub> | 0.36       |
| 49  | 32.4029  | 1-Tetradecanol  | C <sub>14</sub> H <sub>30</sub> O              | 0.11       |
| 50  | 32.6169  | Heptadecanoic acid, ethyl ester   | C <sub>19</sub> H <sub>38</sub> O <sub>2</sub> | 0.08       |
| 51  | 32.7238  | 10-Heptadecen-8-ynoic acid, methyl ester, (E)-                            | C <sub>18</sub> H <sub>30</sub> O <sub>2</sub> | 0.08       |
| 52  | 32.9913  | Phytol  | C <sub>20</sub> H <sub>40</sub> O              | 18.14      |
| 53  | 33.3924  | 9,12-Octadecadienoic acid (Z,Z)-  | C <sub>18</sub> H <sub>32</sub> O <sub>2</sub> | 3.92       |
| 54  | 33.5422  | 9,12,15-Octadecatrienoic acid, (Z,Z,Z)-                                   | C <sub>18</sub> H <sub>30</sub> O <sub>2</sub> | 10.39      |
| 55  | 33.8150  | Linoleic acid ethyl ester   | C <sub>20</sub> H <sub>36</sub> O <sub>2</sub> | 0.70       |
| 56  | 33.8899  | Octadecanoic acid   | C <sub>18</sub> H <sub>36</sub> O <sub>2</sub> | 1.16       |
| 57  | 33.9327  | 9,12,15-Octadecatrienoic acid, ethyl ester, (Z,Z,Z)-                      | C <sub>20</sub> H <sub>34</sub> O <sub>2</sub> | 1.74       |
| 58  | 34.3980  | Octadecanoic acid, ethyl ester  | C <sub>20</sub> H <sub>40</sub> O <sub>2</sub> | 0.26       |
| 59  | 34.4782  | Octadecane  | C <sub>18</sub> H <sub>38</sub>                | 0.14       |

| No. | TR (min) | Compound name  | Molecular formula                               | % of Total |
|-----|----------|--|---|------------|
| 60  | 34.8312  | Phytol, acetate  | C <sub>22</sub> H <sub>42</sub> O <sub>2</sub>  | 0.04       |
| 61  | 35.9117  | Octanoic acid, 2-dimethylaminoethyl ester                  | C <sub>12</sub> H <sub>25</sub> NO <sub>2</sub> | 0.14       |
| 62  | 36.1791  | Pentacosane  | C <sub>25</sub> H <sub>52</sub>                 | 0.25       |
| 63  | 36.3717  | Palmitoyl chloride   | C <sub>16</sub> H <sub>31</sub> ClO             | 0.16       |
| 64  | 37.0403  | 4,8,12,16-Tetramethylheptadecan-4-olide                    | C <sub>21</sub> H <sub>40</sub> O <sub>2</sub>  | 0.13       |
| 65  | 37.2489  | Eicosanoic acid  | C <sub>20</sub> H <sub>40</sub> O <sub>2</sub>  | 0.20       |
| 66  | 37.7784  | Eicosanoic acid, ethyl ester                               | C <sub>22</sub> H <sub>44</sub> O <sub>2</sub>  | 0.11       |
| 67  | 37.8533  | Tetracosane  | C <sub>24</sub> H <sub>50</sub>                 | 0.47       |
| 68  | 39.7734  | Pentacosane  | C <sub>25</sub> H <sub>52</sub>                 | 1.01       |
| 69  | 39.9072  | Hexadecanoic acid, 2-hydroxy-1-(hydroxymethyl) ethyl ester | C <sub>19</sub> H <sub>38</sub> O <sub>4</sub>  | 0.33       |
| 70  | 41.3246  | Hexacosane   | C <sub>26</sub> H <sub>54</sub>                 | 0.96       |
| 71  | 42.5120  | Ethyl (9Z,12Z)-9,12 Octadecanoate                          | C <sub>20</sub> H <sub>36</sub> O <sub>2</sub>  | 0.26       |
| 72  | 42.5708  | Heptacosane  | C <sub>27</sub> H <sub>56</sub>                 | 0.66       |
| 73  | 43.6192  | Tricosane  | C <sub>23</sub> H <sub>48</sub>                 | 0.25       |
| 74  | 43.9026  | Squalene   | C <sub>30</sub> H <sub>50</sub>                 | 1.25       |
| 75  | 44.5498  | Pentatriacontane   | C <sub>35</sub> H <sub>72</sub>                 | 0.13       |
| 76  | 44.9617  | 2,8-Dimethyl-2-(4,8,12-trimethyl tridecyl)-6-chromanol     | C <sub>27</sub> H <sub>46</sub> O <sub>2</sub>  | 0.61       |
| 77  | 45.8282  | gamma.-Tocopherol  | C <sub>28</sub> H <sub>48</sub> O <sub>2</sub>  | 0.25       |
| 78  | 46.4486  | Vitamin E  | C <sub>29</sub> H <sub>50</sub> O <sub>2</sub>  | 0.21       |
| 79  | 47.3633  | Stigmasterol   | C <sub>29</sub> H <sub>48</sub> O               | 1.98       |
| 80  | 47.7591  | Stigmast-5-en-3-ol   | C <sub>29</sub> H <sub>50</sub> O               | 0.20       |
| 81  | 48.0105  | beta-Amyrin  | C <sub>30</sub> H <sub>50</sub> O               | 0.54       |
| 82  | 49.9734  | 3 beta.-Myristoylolean-12-en-16.beta.-ol                   | C <sub>44</sub> H <sub>76</sub> O <sub>3</sub>  | 0.58       |
| 83  | 53.4554  | Betulin  | C <sub>30</sub> H <sub>50</sub> O <sub>2</sub>  | 8.56       |

The 5 main chemical components found in LEGI were Phytol (18.14 %), n-Hexadecanoic acid (12.45%), 9, 12-Octadecadienoic acid (Z,Z)-(3.92%), 9,12,15-Octadecatrienoic acid, (Z,Z,Z)-(10.39 %), and Betulin (8.56 %) as shown in **Table 2**.

**Table 2** The 5 main chemical compounds found in LEGI.

| Compound name                                     | Molecular formula                               | Groups/activities  |
|---|---|--|
| n-Hexadecanoic acid (12.45%)                      | C <sub>16</sub> H <sub>32</sub> O <sub>2</sub>  | Saturated fatty acid<br>Anti-inflammatory and antioxidant [23-26]  |
| Phytol (18.14 %)                                  | C <sub>20</sub> H <sub>40</sub> O               | Diterpene compound<br>Antioxidant, anti-inflammatory and antihyperglycemic [26-32]                               |
| 9,12-Octadecadienoic acid, (Z,Z)- (3.92%)         | C <sub>18</sub> H <sub>32</sub> O <sub>2</sub>  | Unsaturated fatty acid (Essential fatty acid)<br>Inhibitory effect on $\alpha$ -glucosidase and antioxidant [34] |
| 9,12,15-Octadecatrienoic acid, (Z,Z,Z)- (10.39 %) | C <sub>18</sub> H <sub>30</sub> O <sub>2</sub>  | Unsaturated fatty acid (Essential fatty acid)<br>Antioxidant and hypoglycemic [35]                               |
| Betulin (8.56 %)                                  | C <sub>30</sub> H <sub>50</sub> NO <sub>2</sub> | Triterpene<br>Anti-inflammatory and antidiabetic [37,38]   |

Based on the results in **Table 2**, the 5 main compounds found in LEGI were fatty acid both saturated (n-Hexadecanoic acid) and unsaturated fatty acid (9,12-Octadecadienoic acid, (Z,Z)- and 9,12,15-Octadecatrienoic acid, (Z,Z,Z)-), diterpene (Phytol), and triterpene (Betulin). Wongnoppavich *et al.* [12] found that total phenolic and flavonoid contents were more intensive in GI ethanolic extracts. Moreover, polyphenols and flavonoids are the major compounds in GI leaf extract [4].

Pharmacological activities of active compounds have been reported. n-Hexadecanoic acid has anti-inflammatory and antioxidant activities [23-26]. Phytol has antioxidant, anti-inflammatory and antihyperglycemic activities [26-33]. 9,12-Octadecadienoic acid, (Z,Z)- has inhibitory effect on  $\alpha$ -glucosidase and antioxidant activities [34]. 9,12,15-Octadecatrienoic acid, (Z,Z,Z)- has anti-oxidant and hypoglycemic activities [35-36]. Betulin has anti-inflammatory and antidiabetic activities [37,38]. The results from the present study suggest that LEGI are rich with various bioactive compounds including the anti-inflammatory compound such as n-Hexadecanoic acid and Phytol, the hypoglycemic/anti-hyperglycemic/anti-diabetic compounds such as Phytol, 9,12-Octadecadienoic acid, (Z,Z)- and 9,12,15-Octadecatrienoic acid, (Z,Z,Z)- and the antioxidant compounds such as n-Hexadecanoic acid, phytol, 9,12-Octadecadienoic acid, (Z,Z)- and 9,12,15-Octadecatrienoic acid, (Z,Z,Z)-.

### Cytotoxicity

Investigation on cytotoxicity of LEGI in the RAW 264.7 cells after treating with various concentrations of LEGI (25 to 1,000  $\mu\text{g/mL}$ ) using MTT assay revealed that cytotoxicity was found when LEGI at the concentrations higher than 100  $\mu\text{g/mL}$  were applied. The cell viability of the RAW 264.7 cells were  $97.45 \pm 1.67$ ,  $77.97 \pm 2.13$ ,  $64.19 \pm 2.82$ ,  $25.83 \pm 3.62$ ,  $8.06 \pm 1.26$ ,  $5.11 \pm 0.74$ ,  $2.13 \pm 0.02$ ,  $2.10 \pm 0.02$ , and  $2.12 \pm 0.02$  % after treating with LEGI at the concentrations of 25, 50, 100, 150, 200, 250, 500, 750, and 1000  $\mu\text{g/mL}$ , respectively (**Table 3**).

**Table 3** Cell viability of RAW 246.7 cells after treating with LEGI.

| Concentrations<br>( $\mu\text{g/mL}$ ) | Cell viability of RAW 246.7 cells<br>LEGI + LPS 1 $\mu\text{g/mL}$ |                                  |
|--|--|----------------------------------|
|  | (%)  | (IC <sub>50</sub> )              |
| 25                                     | $128.82 \pm 1.97^s$  |                                  |
| 50                                     | $115.46 \pm 2.39^f$  |                                  |
| 100                                    | $83.27 \pm 2.62^c$   |                                  |
| 150                                    | $46.19 \pm 2.82^d$   |                                  |
| 200                                    | $25.83 \pm 3.62^c$   | $128.77 \pm 2.82 \mu\text{g/mL}$ |
| 250                                    | $8.06 \pm 1.26^b$  |                                  |
| 500                                    | $5.97 \pm 0.74^b$  |                                  |
| 750                                    | $2.26 \pm 0.12^a$  |                                  |
| 1000                                   | $2.02 \pm 0.57^a$  |                                  |

Values are expressed as mean  $\pm$  SEM of 3 independent experiments. Mean  $\pm$  SEM followed by different superscripts<sup>(a,b,c)</sup> in the same column indicate significant differences at  $p < 0.05$ .

LEGI at the concentrations of 25, 50 and 100  $\mu\text{g/mL}$  exhibited the cell viability values of the RAW 246.7 cells more than 80%. Thus they were used further to investigate NO production. LEGI exhibited cytotoxicity on the RAW 246.7 cells with IC<sub>50</sub> of  $128.77 \pm 2.82 \mu\text{g/mL}$  (**Table 4**). This result was not consistent with the published reports. No adverse reactions were found in a long-term study of insulin-dependent diabetic patients who consumed or received GI in any form [39,40]. In an acute toxicity study in mice, alterations of gross behavioral, neurological, or autonomic effects did not occur. The acute LD<sub>50</sub> was 3990 mg/kg. The safety ratio (LD<sub>50</sub>/ED<sub>50</sub>) was 11 and 16 in normal and diabetic rats, respectively [39, 41,42]. No side effects were found upon the administration of GI at doses of 504 - 563 mg/kg/d in men [43]. GI extract revealed non-toxic in mice liver and kidney [1]. The reliable toxic dose of GI has not been found. The LD<sub>50</sub> in mice and rats is greater than 5 g/kg [44].

### NO production

NO production quantified by measuring nitrite concentration revealed that LEGI at the concentrations of 25, 50 and 100  $\text{mg/mL}$  inhibited NO production in the LPS-stimulated RAW 264.7 cells concentration-dependently by  $14.07 \pm 1.82$ ,  $16.73 \pm 1.52$  and  $28.30 \pm 1.24$  %, respectively. At the concentration of 50  $\mu\text{g/mL}$ ,

LEGI inhibited NO production in the LPS-stimulated RAW264.7 cells less potent than Diclofenac did ( $16.73 \pm 1.52$  % vs.  $27.07 \pm 1.81$  %) as shown in **Table 4**.

During inflammation, free radical molecule such as NO is generated by inflammatory cells. LEGI inhibited NO production in the LPS-stimulated RAW 264.7 cells suggesting the anti-inflammatory activity of LEGI. This result is concomitant with the study by Wongnoppavich *et al.* [12] who found that GI leaf extract possessed anti-inflammatory effects by inhibiting the NO production in the LPS-activated RAW 264.7 macrophages.

**Table 4** Inhibition on NO production (%) in the LPS-stimulated RAW 246.7 cells.

| Concentrations<br>( $\mu\text{g/ml}$ ) | Inhibition on NO production (%) |                    |
|--|---------------------------------|--------------------|
|  | LEGI                            | Diclofenac         |
| 25                                     | $14.07 \pm 1.82^a$              | -                  |
| 50                                     | $16.73 \pm 1.52^{aA}$           | $27.07 \pm 1.81^B$ |
| 100                                    | $28.30 \pm 1.24^b$              | -                  |

Values are expressed as mean  $\pm$  SEM of 3 independent experiments. Mean  $\pm$  SEM followed by different superscripts <sup>(a,b,c)</sup> in the same column and different superscripts <sup>(A,B)</sup> in the same row indicate significant differences at  $p < 0.05$ .

#### Inhibition on $\alpha$ -glucosidase activity

The *in vitro* enzymatic model revealed that LEGI exhibited significant inhibitory activity against  $\alpha$ -glucosidase concentration-dependently by  $16.50 \pm 0.02$ ,  $23.12 \pm 0.02$ ,  $38.35 \pm 0.04$ ,  $51.34 \pm 0.05$ ,  $59.86 \pm 0.02$ , and  $67.47 \pm 0.03$  % at the concentrations of 0.04, 0.08, 0.16, 0.31, 0.63 and 1.25mg/mL, respectively with  $IC_{50}$  of 0.31 mg/mL. However, at the same concentrations, its activity was less potent than that of Acarbose, a positive control which was  $19.40 \pm 0.04$ ,  $30.38 \pm 0.00$ ,  $48.85 \pm 0.01$ ,  $63.60 \pm 0.20$ ,  $71.39 \pm 0.21$  and  $82.80 \pm 0.01$ % respectively with  $IC_{50}$  of 0.20 mg/mL. The results are summarized in **Table 5** and **Figures 2** and **6**. The results are in line with the study by Srinuanchai *et al.* [13] who found that the ethanolic extract of GI exhibited an inhibitory effect on  $\alpha$ -glucosidase. The GI hypoglycemic effect of GI has been documented, such as consumption of GI tea with a meal or 15 min after a meal can significantly decrease peak plasma glucose [3]. GI exhibited hypoglycemic effect caused by triterpenoid saponins or gymnemic acids (GA) which inhibited glucose absorption from the intestinal tract and suppress the increase in blood glucose level in oral glucose tolerance tests in rats [47]. GA is thought to help the body maintain healthy blood glucose levels [45], can improve and restore the blood vessel which damaged by hyperglycemia in diabetes mellitus [46].


GI ethanol extract significantly delayed glycemic absorption by lowering  $\alpha$ -glucosidase activity [11]. The antidiabetic or hypoglycemic effect of GI is a property of a substance called gymnemic acid [45]. The component of GI extract inhibited the increase in the blood glucose level by interfering with intestinal glucose absorption [47,48]. The GI leaf extract administered to the patient stimulates the pancreas and increases the release of insulin [49]. However, Chiabchalard *et al.* found that the hypoglycemic effect of GI does not relate to increase insulin secretion or inhibition of the  $\alpha$ -glucosidase enzyme [3]. Anti-glycemic properties of the GI leaf extract were dependent on ethanol concentrations [11]. Moreover, the hypoglycemic effect of GI was dose-dependent. Nevertheless, GI tea had no effect on blood sugar in type 2 diabetic patients, this might be due to insufficient doses [14].

**Table 5** Inhibitory effect of LEGI on  $\alpha$ -glucosidase activity.

| Samples | Concentrations<br>(mg/mL) | Inhibitory effect on $\alpha$ -glucosidase activity |                   |
|---------|---------------------------|---|-------------------|
|         |                           | % Inhibition  | $IC_{50}$ (mg/mL) |
| LEGI    | 0.04                      | $16.50 \pm 0.02^a$                                  | 0.31 <sup>b</sup> |
|         | 0.08                      | $23.12 \pm 0.02^b$                                  |                   |
|         | 0.16                      | $38.35 \pm 0.04^c$                                  |                   |
|         | 0.31                      | $51.34 \pm 0.05^d$                                  |                   |
|         | 0.63                      | $59.86 \pm 0.02^e$                                  |                   |
|         | 1.25                      | $67.47 \pm 0.03^f$                                  |                   |

| Samples  | Concentrations<br>(mg/mL) | Inhibitory effect on $\alpha$ -glucosidase activity |                          |
|----------|---------------------------|---|--------------------------|
|          |                           | % Inhibition  | IC <sub>50</sub> (mg/mL) |
| Acarbose | 0.04                      | 19.40 ± 0.04 <sup>a</sup>                           | 0.20 <sup>a</sup>        |
|          | 0.08                      | 30.38 ± 0.00 <sup>c</sup>                           |                          |
|          | 0.16                      | 48.85 ± 0.01 <sup>d</sup>                           |                          |
|          | 0.31                      | 63.60 ± 0.20 <sup>f</sup>                           |                          |
|          | 0.63                      | 71.39 ± 0.21 <sup>g</sup>                           |                          |
|          | 1.25                      | 82.80 ± 0.01 <sup>h</sup>                           |                          |

Values are expressed as mean ± SEM of 3 independent experiments. Mean ± SEM followed by different superscripts<sup>(a,b,c,...)</sup> in the same column indicate significant differences at  $p < 0.05$ .



**Figure 2** Inhibitory effect of Acarbose on  $\alpha$ -glucosidase activity (IC<sub>50</sub>).

### DPPH scavenging activity


DPPH radical scavenging assay showing in **Table 6** demonstrated that LEGI at the concentrations of 0.2, 0.4 and 0.8 mg/mL exhibited concentration-dependently DPPH radical scavenging activity (**Figure 3**) by 29.24±1.06, 43.43±3.04 and 54.39±2.10 %, respectively with IC<sub>50</sub> of 0.41 mg/mL. At the same concentrations, LEGI exhibited DPPH radical scavenging activity significantly ( $p < 0.05$ ) less than BHT did (47.80±0.63, 60.14±0.77 and 80.69±0.64 %, respectively (**Figure 3**) with IC<sub>50</sub> of 0.36 mg/mL). This result is in agreement with that in previously published literature. Wongnoppavich *et al.* [12] reported the ethanolic extract from GI leaves exhibited free radical scavenging effect on the DPPH assay.

Many published data highlight the antioxidant activity of GI and the phytochemical compounds which may act as antioxidants. The chemicals such as vitamin C, vitamin E, carotenoids, and phenolic compounds are contributors to the antioxidant activity in GI [8]. GI juice exhibited the strongest antioxidant activity, partly due to the presence of high amount of vitamin E and  $\beta$ -carotene [10]. GI exhibited the highest antioxidant activity when compared to *Piper sarmentosum* and *Mentha arvensis* [8]. Total phenolic and flavonoid contents in the GI ethanolic leaf extract exhibited DPPH radical scavenging effect [12]. Water and ethanol extracts of GI leaves showed high antioxidant activity with polyphenols as the major antioxidant [16]. Moreover, antioxidant potential may be due to the conditions of extraction such as the extracted solvents and the process of extraction. The fresh juice of GI had the highest antioxidant activity compared to GI water extract and 50 % ethanol extract [2]. The antioxidant activity using DPPH assay was significantly different in GI tea process [50]. Additionally, antioxidant capacity of GI was mainly owing to the presence of water-soluble compounds [19].

**Table 6** Effect of LEGI on DPPH scavenging activity (%).

| Samples | Concentrations (mg/mL) | % DPPH scavenging         | IC <sub>50</sub> (mg/mL) |
|---------|------------------------|---------------------------|--------------------------|
| LEGI    | 0.2                    | 29.24 ± 1.06 <sup>a</sup> | 0.41                     |
|         | 0.4                    | 43.43 ± 3.04 <sup>b</sup> |                          |
|         | 0.8                    | 54.39 ± 2.10 <sup>c</sup> |                          |
| BHT     | 0.2                    | 47.80 ± 0.63 <sup>b</sup> | 0.36                     |
|         | 0.4                    | 60.14 ± 0.77 <sup>d</sup> |                          |
|         | 0.8                    | 80.69 ± 0.64 <sup>e</sup> |                          |

Values are expressed as mean ± SEM of 3 independent experiments. Mean ± SEM followed by different superscripts<sup>(a,b,c)</sup> in the same column indicate significant differences at  $p < 0.05$ .

**Figure 3** Effect of BHT on DPPH scavenging activity (IC<sub>50</sub>).

The chemicals compounds with antioxidant activity, such as n-hexadecanoic acid, hexadecanoic acid ethyl ester and 9, 12, 15-octadecatrienoic acid, ethyl ester (Z,Z,Z) were found in LEGI. Therefore, the antioxidant activity of LEGI may be due to the synergistic effects of these compounds.

## Conclusions

This study, the ethanolic leaf extract of *G. inodorum* exhibits anti-inflammatory, antidiabetic and antioxidant activities. The most predominant compound is n-Hexadecanoic acid followed by Phytol. The extract exhibits anti-inflammatory activity by inhibition of NO production, displays antidiabetic activity via inhibition on  $\alpha$ -glucosidase activity, and shows antioxidant activity by DPPH radical scavenging. Besides, it exerts relatively low cytotoxicity to the RAW 264.7 cells, by MTT assay. Thus, the ethanolic leaf extract of *G. inodorum* could be considered as a good natural source for the development of novel anti-inflammatory, antidiabetic and antioxidant agents. Due to these activities of the extract has not been conducted directly, the mechanism of actions especially in in vivo and the active compounds which are responsible to these activities are needed to perform.

## Acknowledgements

The authors gratefully acknowledge the financial support provided by the Faculty of Science and Technology, Rajamangala University of Technology Thanyaburi (RMUTT), Pathum Thani, Thailand.

## References

- [1] K Tiomyom, K Sirichaiwetchakoon, T Hengpratom, S Kuppitayanant, R Srisawat, A Thaeomor and G Eumkeb. The effects of *Cordyceps sinensis* (Berk.) Sacc. and *Gymnema inodorum* (Lour.) Decne. Extracts on adipogenesis and lipase activity in vitro. *Evid. Based Complement. Altern. Med.* 2019; **2019**, 5370473.
- [2] N Chongviriyaphan, T Muangman, C Pisalpong, NP Molarese, P Klungsupya, U Suthutvoravut. Antioxidant activity of *Gymnema inodorum* Decne. (Pak chiang daa) and its effect on DNA damage. *FASEB J.* 2006; **20**, LB90-LB90.
- [3] A Chiabchalard, T Tencomnao and R Santiyanont. Effect of *Gymnema inodorum* on postprandial peak plasma glucose levels in healthy human. *Afr. J. Biotechnol.* 2010; **9**, 1079-85.
- [4] B Dunkhunthod, C Talabnin, M Murphy, K Thumanu, P Sittisart and G Eumkeb. *Gymnema inodorum* (Lour.) Decne. Extract alleviates oxidative stress and inflammatory mediators produced by RAW264.7 macrophages. *Oxid. Med. Cell. Longev.* 2021; **2021**, 8658314.
- [5] MPT Maw and N Piyapolrunroj. Effect of *Gymnema inodorum* on P-glycoprotein function: An *in vitro* study. In: Proceedings of the 5<sup>th</sup> International Conference on Pharmaceuticals, Nutraceuticals and Cosmetic Science, Bangkok, Thailand. 2017, p. 153-6.
- [6] A Saneja, C Sharma, K Aneja and R Pahwa. *Gymnema sylvestre* (Gurmar): A review. *Pharm. Lett.* 2010; **2**, 275-84.
- [7] P Yingthongchai, P Sirikhum, S Nilsamranchit and S Tateing. Comparison of nutritional value and bioactive compounds in *Gymnema inodorum* Decne. leaves. *J. Agr.* 2018; **34**, 363-72.
- [8] A Chanwitheesuk, A Teerawutgulrag and N Rakariyatham. Screening of antioxidant activity and antioxidant compounds of some edible plants of Thailand. *Food Chem.* 2005, **92**, 491-7.
- [9] DT Trang, DTH Yen, NT Cuong, LT Anh, NT Hoai, BH Tai, VV Doan, PH Yen, TH Quang, NX Nhiem, CV Minh and PV Kiem. Pregnane glycosides from *Gymnema inodorum* and their  $\alpha$ -glucosidase inhibitory activity. *Nat. Prod. Res.* 2019; **35**, 2157-63.
- [10] T Muangman, N Chongviriyaphan, C Pisalpong, NP Molarese, P Klungsupya. Free radical scavenging activity of *Gymnema inodorum* Decne extracts. *J. Nutr. Assoc. Thai.* 2007; **42**, 19-28.
- [11] W Srinuanchai, R Nooin, P Pitchakarn, J Karinchai, U Suttisansanee, C Chansrinियom, S Jarussophon, P Onanong and Nuchuchua. Inhibitory effects of *Gymnema inodorum* (Lour.) Decne. leaf extracts and its triterpene saponin on carbohydrate digestion and intestinal glucose absorption. *J. Ethnopharmacol.* 2021; **10**, 113-398.
- [12] A Wongnoppavich, A Bonness and N Waloh. 2014, Effects of ethanolic extracts from *Azadirachta indica* and *Gymnema inodorum* leaves on anti-inflammation in macrophage and anti-insulin resistance in adipocyte. Master's thesis. Chiang Mai University, Chiang Mai, Thailand.
- [13] W Srinuanchai, P Pitchakarn, S Jarussophon and O Nuchuchua. Antidiabetic phytoconstituents and cytotoxicity of *Gymnema inodorum* (Lour.) Decne leaf extract, Available at: <https://www.semanticscholar.org/paper/Antidiabetic-phytoconstituents-and-cytotoxicity-of-Srinuanchai-Pitchakarn/509d9f0a30e427281a13c19862879f1dc4e8685c#paper-header>.
- [14] R Besspinyowong, S Pongthanakorn and A Chiabchalard. Efficacy and safety of *Gymnema inodorum* tea consumption in type 2 diabetic patients. *Chula. Med. J.* 2013, **57**, 587-99.
- [15] JP An, EJ Park, B Ryu, BW Lee, HM Cho, TP Doan, HTT Pham and WK Oh. Triterpenoids from the leaves of *Gymnema inodorum* and their insulin mimetic activities. *J. Nat. Prod.* 2020, **83**, 1265-74.
- [16] P Klungsupya, T Muangman, N Theangtrong, A Khayungarnawee, W Phatvej, K thisayakorn, U Rerk-Am, T Sematong, S Trangvacharakul and V Arunpairojana. Antioxidant and antihyperglycemic activities of *Gymnema inodorum* Dence. In: Proceedings of the 8<sup>th</sup> NRCT-JSPS Joint Seminar WInnovative Research in Natural Products for Sustainable Development, Chulalongkorn University. 2008, p. 1-3.
- [17] P Klungsupya, T Muangman, N Theangtrong, A Khayungarnawee, W Phatvej, K Thisayakorn, U Rerk-Am, T Sematong, S Trangvacharakul, V Arunpairojana. Antioxidant and antihyperglycemic activities of *Gymnema inodorum* Dence. In: Proceedings of the 9<sup>th</sup> NRCT-JSPS Joint Seminar Innovative Research in Natural Products for Sustainable Development, Bangkok, Thailand, 2009, p. 207-9.
- [18] W Keapai, P Toejing, J Intakhad, P Saengratwatchara, T Tangjai and N Lailerd. Anti-diabetic activity of *Gymnema inodorum* extract in high-fat diet and streptozotocin-induced diabetic rats: Preliminary study. In: Proceedings of the 1<sup>st</sup> International Conference on Innovation of Functional Foods in Asia. University of Phayao, Phayao, Thailand. 2018, p. 1-19.

- [19] J Thongdon-A, P Klungsunya, T Muangman, A Tantrawong and S Trangvacharakul. Use of three Thai indigenous vegetables as potential dietary fiber sources for health food product. *Thai. J. Pharm. Sci.* 2013; **38**, 48-51.
- [20] N Buddhakala and C Talubmook. Toxicity and antidiabetic activity of ethanolic extract of *Sphagneticola trilobata* (L.) Pruski flower in rats. *J. Ethnopharmacol.* 2020, **262**, 113-28.
- [21] JV Meerloo, GJL Kaspers and J Cloos. Cell sensitivity assays: The MTT assay. *Meth. Mol. Bio.* 2011; **731**, 237-45.
- [22] HQ Dong, M Li, F Zhu, FL Liu and JB Huang. Inhibitory potential of trilobatin from *Lithocarpus polystachyus* Rehd against  $\alpha$ -glucosidase and  $\alpha$ -amylase linked to type 2 diabetes. *Food Chem.* 2012; **30**, 261-6.
- [23] V Aparna, V Dileep, M Pradeep, K Ponnuraj, S Chittalakkottu and M Haridas. Anti-Inflammatory property of n-Hexadecanoic acid: Structural evidence and kinetic assessment. *Chem. Biol. Drug Des.* 2012; **80**, 434-9.
- [24] SU Ponnamma and K Manjunath. GC-MS analysis of phytochemicals in the methanolic extract of *Justicia wyaadensis* (Nees) T. Anders. *Int. J. Pharm. Bio Sci.* 2012; **3**, P570-P576.
- [25] PN Ruvanthika, S Manikandan and S Lalitha. A comparative study on phytochemical screening of aerial parts of *Nelumbo nucifera* Gaertn by gas chromatographic mass spectrometry. *Int. J. Pharm. Sci. Res.* 2016; **8**, 2258-66.
- [26] S Chitra and J Karthikeyan. Phytochemical profiling of cat whisker's (*Orthosiphon stamineus*) tea leaves extract. *J. Pharmacogn. Phytochem.* 2018; **7**, 1396-402.
- [27] CCMP Santos, MS Salvadori, VG Mota, LM Costa, AACO Almeida GALD Oliveira, JP Costa, DPD Sousa, RMD Freitas and RND Almeida. Antinociceptive and antioxidant activities of phytol *in vivo* and *in vitro* models. *Neurosci J.* 2013; **2013**, 949452.
- [28] JP Costa, MT Islam, PS Santos, PB Ferreira, GL Oliveira, MV Alencar, MF Paz, ÉL Ferreira, CM Feitosa, AM Citó, DP Sousa, AA Melo-Cavalcante. Evaluation of antioxidant activity of phytol using non- and pre-clinical models. *Curr. Pharm. Biotechnol.* 2016; **17**, 1278-84.
- [29] JD Moraes, RND Oliveira, JP Costa, ALG Junior, DPD Sousa, RM Freitas, SM Allegretti, PLS Pinto. Phytol, a diterpene alcohol from chlorophyll, as a drug against neglected tropical disease *Schistosomiasis mansoni*. *PLoS Negl. Trop. Dis.* 2014; **8**, e2617.
- [30] KR Ryu, JY Choi, S Chung and DH Kim. Anti-scratching behavioral effect of the essential oil and phytol isolated from *Artemisia princeps* Pamp. in mice. *Planta Med.* 2011; **77**, 22-6.
- [31] MT Islam, SA Ayatollahi, SM Neamul, K Zihad, N Sifat, MdR Khan, A Paul, B Salehi, T Islam, MS Mubarak, N Martins and J Sharifi-Rad. Phytol anti-inflammatory activity: Pre-clinical assessment and possible mechanism of action elucidation. *Cell. Mol. Biol.* 2020; **66**, 264-9.
- [32] RO Silva, FB Sousa, SR Damasceno, NS Carvalho, VG Silva, FR Oliveira, DP Sousa, KS Aragão, AL Barbosa, RM Freitas and JV Medeiros. Phytol, a diterpene alcohol, inhibits the inflammatory response by reducing cytokine production and oxidative stress. *Fundam. Clin. Pharmacol.* 2014; **28**, 455-64.
- [33] HC Upadhyay, A Mishra, J Pandey, P Sharma, AK Tamrakar, AK Srivastava, F Khan and SK Srivastava. *In vitro*, *in vivo* and *in silico* antihyperglycemic activity of some semi-synthetic phytol derivatives. *Med. Chem.* 2022; **18**, 115-21.
- [34] S Gunasekarana, T Vijay, K Sarumathy, S Palanie, RPS Panneerselvamb and V Srinivasanba. Phytoconstituents evaluation by GC-MS and therapeutic efficacy of *Grewia umbellifera* on Streptozotocin (STZ) induced diabetic. *Int. J. Pharm. Sci.* 2013; **4**, 2380-6.
- [35] DE Barre. The role of consumption of alpha-linolenic, eicosapentaenoic and docosahexaenoic acids in human metabolic syndrome and type 2 diabetes - a mini-review. *J. Oleo Sci.* 2007; **56**, 319-25.
- [36] N Blondeau, RH Lipsky, M Bourourou, MW Duncan, PB Gorelick and AM Marini. Alpha-linolenic acid: An omega-3 fatty acid with neuroprotective properties - Ready for use in the stroke clinic. *BioMed Res. Int.* 2015; **2015**, 519830.
- [37] X Ci, J Zhou, Lv Hongming, Q Yu, L Peng and S Hua. Betulin exhibits anti-inflammatory activity in LPS-stimulated macrophages and endotoxin-shocked mice through an AMPK/AKT/Nrf2-dependent mechanism. *Cell Death Dis.* 2017; **8**, e2798.
- [38] A Boparai, J Niazi, N Bajwa and PA Singh. Betulin a pentacyclic tri-terpenoid: An hour to rethink the compound. *J. Transl. Med. Res.* 2017; **1**, 53-9.
- [39] GS Thakur, R Sharma, BS Sanodiya, M Pandey, G Prasad and PS Bisen. *Gymnema sylvestre*: An alternative therapeutic agent for management of diabetes. *J. Appl. Pharm. Sci.* 2012; **2**, 1-6.

- [40] E Shanmugasundaram, KL Gopinath, KR Shanmugasundaram and V Rajendran. Possible regeneration of the islets of Langerhans in streptozotocin-diabetic rats given *Gymnema sylvestre* leaf extracts. *J. Ethnopharmacol.* 1990; **30**, 265-79.
- [41] HG Preuss, ST Jarrell, R Scheckenbach, S Lieberman and RA Anderson. Comparative effects of chromium, vanadium and *Gymnema sylvestre* on sugar-induced blood pressure elevations in SHR. *J. Am. Coll. Nutr.* 1998; **17**, 116-23.
- [42] R Chattopadhyay. A comparative evaluation of some blood sugar lowering agents of plant origin. *J. Ethnopharmacol.* 1999; **67**, 367-72.
- [43] Y Ogawa, K Sekita, T Umemura, M Saito, A Ono, Y Kawasaki, O Uchida, Y Matsushima, T Inoue and J Kanno. *Gymnema sylvestre* leaf extract: A 52-week dietary toxicity study in Wistar rats. *Shokuhin Eiseigaku zasshi.* 2004; **45**, 8-18.
- [44] J Wungrath. Antidiabetic activity of Chiang Da (*Gymnema inodorum*) local plant of Northern Thailand. *Eur. J. Mol. Clin. Med.* 2020; **7**, 4710-17.
- [45] S Nair and R Keshavachandran. Genetic variability of chakkarakolli (*Gymnema sylvestre* R. Br.) in Kerala assessed using morphological and biochemical markers. *J. Trop. Agr.* 2006; **44**, 64-6.
- [46] N Sandech. 2019, Efficiency of Gymnemic acid from *Gymnema sylvestre* for restoration and improvement of brain vascular characteristic in diabetic rat. Master's thesis. Prince of Songkla University, Songkla, Thailand.
- [47] K Shimizu, M Ozeki, K Tanaka, K Itoh, S Nakjyo, N Urakawa and M Atsuchi. Suppression of glucose absorption by extracts from the leaves of *Gymnema inodorum*. *J. Vet. Med. Sci.* 1997; **59**, 753-7.
- [48] K Shimizu, M Ozeki, A Iino, S Nakajyo, N Urakawa and M Atsuchi. Structure-activity relationship of triterpenoid derivatives extracted from *Gymnema inodorum* leaves on glucose absorption. *Jpn. J. Pharmacol.* 2002; **86**, 223-9.
- [49] P Kanetkar, K Laddha and M Kamat. Gymnemic acids: A molecular perspective of its action on carbohydrate metabolism. In: Proceedings of the 16<sup>th</sup> Indian Convention of Food Scientists and Technologists, Mysore, India. 2004.
- [50] N Taokaenchan, K Areesrisom, P Areesrisom, V Maifaey and S Sateinperakul. Total phenolic compound, flavonoid content and antioxidant activity of *Gymnema inodorum* tea from difference process. *J. Agr. Prod.* 2020; **2**, 51-61.